SLE-BRAVE I and II

Affiliations

¹ Beaumont Hospital, Dublin D09V2N0, Ireland; Royal College of Surgeons of Ireland, Dublin, Ireland. Electronic address: lauradurcan@beaumont.ie.
² Cork University Hospital, Cork, Ireland.

Comment

Laura Durcan et al. Lancet. 2023.

. 2023 Mar 25;401(10381):972-973.

doi: 10.1016/S0140-6736(23)00342-2. Epub 2023 Feb 24.

¹ Beaumont Hospital, Dublin D09V2N0, Ireland; Royal College of Surgeons of Ireland, Dublin, Ireland. Electronic address: lauradurcan@beaumont.ie.
² Cork University Hospital, Cork, Ireland.

No abstract available

Comment on

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. Morand EF, et al. Lancet. 2023 Mar 25;401(10381):1001-1010. doi: 10.1016/S0140-6736(22)02607-1. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848918 Clinical Trial.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M. Petri M, et al. Lancet. 2023 Mar 25;401(10381):1011-1019. doi: 10.1016/S0140-6736(22)02546-6. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848919 Clinical Trial.